Life-threatening thyrotoxicosis induced by combination therapy with PEG-interferon and ribavirin in chronic Hepatitis C

Endocrine Practice

Volumn 11, Issue 2, 2005, Pages 135-139

  Lin, Yong Q ^a   Wang, Xiangbing ^a   Murthy, Meena S ^a   Agarwala, Sumon ^a  

^a SAINT PETER S UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; PEGINTERFERON ALPHA2B; PREDNISONE; PROPRANOLOL; PROPYLTHIOURACIL; RIBAVIRIN;

ADULT; ANAMNESIS; CASE REPORT; CHRONIC DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DISEASE SEVERITY; DRUG DOSE REGIMEN; ECG ABNORMALITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HORMONE DETERMINATION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPERTHYROIDISM; LABORATORY TEST; NAUSEA; NODULAR GOITER; PHYSICAL EXAMINATION; THYROTOXICOSIS; VOMITING;

EID: 18744363904     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.11.2.135     Document Type: Conference Paper

References (13)

1. Shiratori Y, Yokosuka O, Nakata R, et al. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology. 1999;29:1573-1580.
2. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997;336:347-356.
3. Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology. 1997;26:206-210.
4. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283-291.
5. Wong V, Fu AX, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol. 2002;56:793-798.
6. McHutchison JG, Gordon SC, Schiff ER, et al (Hepatitis Interventional Therapy Group). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339: 1485-1492.
7. Carella C, Mazziotti G, Morisco F, et al. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol. 2002;146: 743-749.
8. Mazziotti G, Sorvillo F, Stornaiuolo G, et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest. 2002;25:624-630.
9. Dalgard O, Bjoro K, Hellum K, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med. 2002;251:400-406.
10. Tietgens ST, Leinung MC. Thyroid storm. Med Clin North Am. 1995;79:169-184.
11. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis: thyroid storm. Endocrinol Metab Clin North Am. 1993;22: 263-277.
12. Wolff J, Chaikoff IL, Goldberg RC, Meier JR. The temporary nature of the inhibitory action of excess iodine on organic iodine synthesis in the normal thyroid. Endocrinology. 1949;45:504-513.
13. Eng PH, Cardona GR, Fang SL, et al. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology. 1999;140:3404-3410.